SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001615774-16-008523
Filing Date
2016-11-21
Accepted
2016-11-21 17:27:57
Documents
1
Group Members
VIVO VENTURES FUND VII, L.P.VIVO VENTURES VII AFFILIATES FUND, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A s104773_sc13da.htm SC 13D/A 74658
  Complete submission text file 0001615774-16-008523.txt   76216
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Subject) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89137 | Film No.: 162011205
SIC: 2834 Pharmaceutical Preparations

Mailing Address 575 HIGH STREET #201 PALO ALTO CA 94301
Business Address 575 HIGH STREET #201 PALO ALTO CA 94301 (650) 688-0818
VIVO VENTURES VII, LLC (Filed by) CIK: 0001565020 (see all company filings)

IRS No.: 274484686 | State of Incorp.: DE
Type: SC 13D/A